American Century Companies’s Amylyx Pharmaceuticals AMLX Stock Holding History

American Century Companies’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-134,380	Closed	-$861K	–	2787
2025 Q2	$861K	Buy	134,380 +27,366	+26%	+$133K	﹤0.01%	2347
2025 Q1	$379K	Buy	107,014 +47,704	+80%	+$170K	﹤0.01%	2606
2024 Q4	$224K	Buy	59,310 +38,261	+182%	+$180K	﹤0.01%	2764
2024 Q3	$68.2K	Buy	21,049 +2,008	+11%	+$4.51K	﹤0.01%	2852
2024 Q2	$36.2K	Sell	19,041 -359,757	-95%	-$697K	﹤0.01%	2870
2024 Q1	$1.08M	Sell	378,798 -163,748	-30%	-$2.14M	﹤0.01%	2119
2023 Q4	$7.99M	Buy	+542,546	New	+$8.32M	0.01%	1237

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

American Century Companies's AMLX Position: Q3 2025 in Review

American Century Companies sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 134,380 shares — an estimated $861K sold.

American Century Companies first reported a position in AMLX in Q4 2023 and held it in 7 quarters. The position peaked at $7.99M in Q4 2023. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

American Century Companies reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
American Century Companies sold 134,380 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $861K.
American Century Companies first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 7 quarters.
American Century Companies's Amylyx Pharmaceuticals position peaked at $7.99M in Q4 2023.
169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on American Century Companies's 13F filing for Q3 2025, filed 12 Nov 2025.